Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797999 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
A Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma, sponsored by Adcendo ApS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 8
- Study locations
NCT06797999 is a Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma that is actively recruiting participants, run by Adcendo ApS. The registered enrollment target is 270 participants, above the 118-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (129% higher). The trial reports 8 study locations across 5 states.
The verdict
NCT06797999, a Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Adcendo ApS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Conditions Studied
Interventions
- BIOLOGICAL Antibody-drug conjugate (ADC)
Study Locations (8)
Other
- Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg - Leuven
- Centre Léon Bérard - Lyon
- Universitätsklinikum Essen West German Tumor Center - Essen
- Royal Marsden - London
Colorado
- University of Colorado Denver - Aurora
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University Of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2029-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06797999
The ClinicalTrials.gov registry entry for NCT06797999 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (129% higher). The listed sponsor is Adcendo ApS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Antibody-drug conjugate (ADC) is the first listed.
NCT06797999 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06797999 about?
NCT06797999 is a clinical study titled "First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma". The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
What is the current status of trial NCT06797999?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2025-06-05. Estimated completion is 2029-02-27.
What conditions does trial NCT06797999 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma.
What interventions are being tested in trial NCT06797999?
The interventions under investigation include: Antibody-drug conjugate (ADC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06797999?
This trial is sponsored by Adcendo ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797999 being conducted?
This trial has 8 study locations across Colorado, Florida, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 1
-
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
RECRUITING · Phase 1
-
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Soft Tissue Sarcoma
All registered trials for this condition
Unresectable Soft Tissue Sarcoma
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.